These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37004409)

  • 21. Reliability and Validity of the Self-Report Version of the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder.
    Patel TA; Summers BJ; Wilver NL; Cougle JR
    Assessment; 2023 Sep; 30(6):1935-1946. PubMed ID: 36114713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective pilot study of levetiracetam for body dysmorphic disorder.
    Phillips KA; Menard W
    CNS Spectr; 2009 May; 14(5):252-60. PubMed ID: 19407724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychometric Evaluation of the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder for Adolescents (BDD-YBOCS-A).
    Monzani B; Fallah D; Rautio D; Gumpert M; Jassi A; Fernández de la Cruz L; Mataix-Cols D; Krebs G
    Child Psychiatry Hum Dev; 2023 Dec; 54(6):1799-1806. PubMed ID: 35678889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive behaviour therapy for adolescents with body dysmorphic disorder: a case series.
    Krebs G; Turner C; Heyman I; Mataix-Cols D
    Behav Cogn Psychother; 2012 Jul; 40(4):452-61. PubMed ID: 22494800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Pilot Testing of a Cognitive-Behavioral Therapy Digital Service for Body Dysmorphic Disorder.
    Wilhelm S; Weingarden H; Greenberg JL; McCoy TH; Ladis I; Summers BJ; Matic A; Harrison O
    Behav Ther; 2020 Jan; 51(1):15-26. PubMed ID: 32005333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Prevalence of Body Dysmorphic Disorder and Moderate to Severe Appearance-Related Obsessive-Compulsive Symptoms Among Rhinoplasty Candidates.
    Ramos TD; de Brito MJA; Suzuki VY; Sabino Neto M; Ferreira LM
    Aesthetic Plast Surg; 2019 Aug; 43(4):1000-1005. PubMed ID: 30607575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Cognitive Therapy for Body Dysmorphic Disorder: A Randomized Controlled Pilot Trial.
    Ritter V; Schüller J; Berkmann EM; von Soosten-Höllings-Lilge L; Stangier U
    Behav Ther; 2023 Jan; 54(1):65-76. PubMed ID: 36608978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive-Behavioral Therapy for Adolescent Body Dysmorphic Disorder: A Pilot Study.
    Greenberg JL; Mothi SS; Wilhelm S
    Behav Ther; 2016 Mar; 47(2):213-24. PubMed ID: 26956653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Outcomes of Cognitive-Behavioral Therapy for Adolescent Body Dysmorphic Disorder.
    Krebs G; Fernández de la Cruz L; Monzani B; Bowyer L; Anson M; Cadman J; Heyman I; Turner C; Veale D; Mataix-Cols D
    Behav Ther; 2017 Jul; 48(4):462-473. PubMed ID: 28577583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yale-Brown Obsessive Compulsive Scale modified for Body Dysmorphic Disorder (BDD-YBOCS): Brazilian Portuguese translation, cultural adaptation and validation.
    de Brito MJ; Sabino Neto M; de Oliveira MF; Cordás TA; Duarte LS; Rosella MF; Felix GA; Ferreira LM
    Braz J Psychiatry; 2015; 37(4):310-6. PubMed ID: 26692429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliability and Validity of the Self-Report Chinese Version of the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) in Patients Undergoing Plastic Surgery.
    Chen X; Chen G; Wang J; Huang J
    Aesthetic Plast Surg; 2022 Aug; 46(4):2023-2030. PubMed ID: 35201378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
    Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Kichuk SA; Martins B; Patel P; Schaer H; Shnayder S; Witherow C; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1278823. PubMed ID: 38264632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and impact of insomnia in children and adolescents with body dysmorphic disorder undergoing multimodal specialist treatment.
    Sevilla-Cermeño L; Rautio D; Andrén P; Hillborg M; Silverberg-Morse M; Lahera G; Mataix-Cols D; Fernández de la Cruz L
    Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1289-1299. PubMed ID: 31760510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting response to a smartphone-based cognitive-behavioral therapy for body dysmorphic disorder.
    Greenberg JL; Weingarden H; Hoeppner SS; Berger-Gutierrez RM; Klare D; Snorrason I; Costilla-Reyes O; Talbot M; Daniel KE; Vanderkruik RC; Solar-Lezama A; Harrison O; Wilhelm S
    J Affect Disord; 2024 Jun; 355():106-114. PubMed ID: 38521133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
    Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; Patel P; Amoroso L; Schaer H; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1178529. PubMed ID: 37181888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.